Skip to main content

LMR Partners LLP

Position in XENE — Xenon Pharmaceuticals Inc.

CIK 1578621 LONDON, X0

Position in XENE

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$3,268,030
+$3,268,030 QoQ
Shares Held
56,200
Ownership
0.058%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Jun 2022
11 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in XENE Over Time

Shares Held

Position Value (USD)

Derivatives in XENE

reported options exposure · as of Mar 31, 2026
CallValue
$0
CallShares
0
PutValue
$9,990,170
PutShares
171,800

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

LMR Partners LLP holds $224,816,570 across 60 Biotechnology names. XENE ranks #15 (1.5% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in XENE

Export CSV
13 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $9,990,170 171,800
2026-03-31 $3,268,030 56,200
2025-12-31 $6,982,956 155,800
2024-12-31 $1,907,785 48,668
2024-09-30 $1,916,059 48,668
2024-06-30 $1,897,565 48,668
2024-03-31 $2,095,157 48,668
2023-12-31 $44,125 958
2023-12-31 $4,541,516 98,600
2023-09-30 $854,000 25,000
2022-12-31 $1,971,500 50,000
2022-09-30 $2,371,697 65,698
2022-06-30 $3,042,000 100,000